Rate control in atrial fibrillation

The Lancet

Volumn 388, Issue 10046, 2016, Pages 818-828

  Van Gelder, Isabelle C ^a   Rienstra, Michiel ^a   Crijns, Harry J G M ^b   Olshansky, Brian ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Mercy Medical Center North Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITOXIN; DIGOXIN; DILTIAZEM; ESMOLOL; METOPROLOL; METOPROLOL TARTRATE; NEBIVOLOL; VERAPAMIL; ANTIARRHYTHMIC AGENT; SOTALOL;

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR PARAMETERS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; HEART ATRIUM FLUTTER; HEART HEMODYNAMICS; HEART RATE CONTROL; HUMAN; PACEMAKER IMPLANTATION; PATIENT MONITORING; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SICK SINUS SYNDROME; TREATMENT PLANNING; AGE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CATHETER ABLATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEART ATRIOVENTRICULAR NODE; HEART FAILURE; HEART RATE; PATHOPHYSIOLOGY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATENOLOL; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; BRADYCARDIA; CALCIUM CHANNEL BLOCKERS; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; DIGOXIN; DRUG THERAPY, COMBINATION; HEART FAILURE; HEART RATE; HUMANS; PACEMAKER, ARTIFICIAL; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOTALOL;

EID: 84988461386     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31258-2     Document Type: Review

References (91)

1. 1 Camm, AJ, Kirchhof, P, Lip, GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12 (2010), 1360–1420.
2. 2 Camm, J, Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. Int J Cardiol 155 (2012), 362–371.
3. 3 Wyse, DG, Waldo, AL, DiMarco, JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002), 1825–1833.
4. 4 Van Gelder, IC, Hagens, VE, Bosker, HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002), 1834–1840.
5. 5 Carlsson, J, Miketic, S, Windeler, J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 (2003), 1690–1696.
6. 6 Hohnloser, SH, Kuck, KH, Lilienthal, J, Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356 (2000), 1789–1794.
7. 7 Ogawa, S, Yamashita, T, Yamazaki, T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 73 (2009), 242–248.
8. 8 Opolski, G, Torbicki, A, Kosior, DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126 (2004), 476–486.
9. 9 Roy, D, Talajic, M, Nattel, S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008), 2667–2677.
10. 10 Calkins, H, Kuck, KH, Cappato, R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14 (2012), 528–606.
11. 11 Wilber, DJ, Pappone, C, Neuzil, P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303 (2010), 333–340.
12. 12 Morillo, CA, Verma, A, Connolly, SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311 (2014), 692–700.
13. 13 Packer, DL, Kowal, RC, Wheelan, KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 61 (2013), 1713–1723.
14. 14 Mont, L, Bisbal, F, Hernandez-Madrid, A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J 35 (2014), 501–507.
15. 15 Kirchhof, P, Breithardt, G, Camm, AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 166 (2013), 442–448.
16. 16 January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–76.
17. 17 Van Gelder, IC, Groenveld, HF, Crijns, HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362 (2010), 1363–1373.
18. 18 Wyse, DG, Therapeutic considerations in applying rate control therapy for atrial fibrillation. J Cardiovasc Pharmacol 52 (2008), 11–17.
19. 19 Daoud, EG, Weiss, R, Bahu, M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78 (1996), 1433–1436.
20. 20 Kerr, AJ, Williams, MJ, Stewart, RA, Ventricular rate and beat-to-beat variation of stroke volume in atrial fibrillation. Am J Cardiol 87 (2001), 1116–1119.
21. 21 Santhanakrishnan, R, Wang, N, Larson, MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 (2016), 484–492.
22. 22 Gopinathannair, R, Etheridge, SP, Marchlinski, FE, et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 66 (2015), 1714–1728.
23. 23 Adam, SS, McDuffie, JR, Ortel, TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 157 (2012), 796–807.
24. 24 Hart, RG, Pearce, LA, Aguilar, MI, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
25. 25 Peterson, ED, Ho, PM, Barton, M, et al. ACC/AHA/AACVPR/AAFP/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation 130 (2014), 1984–1994.
26. 26 Kirchhof, P, Breithardt, G, Bax, J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 18 (2016), 37–50.
27. 27 Rawles, JM, What is meant by a “controlled” ventricular rate in atrial fibrillation?. Br Heart J 63 (1990), 157–161.
28. 28 Rienstra, M, Van Gelder, IC, Who, when and how to rate control for atrial fibrillation. Curr Opin Cardiol 23 (2008), 23–27.
29. 29 Fuster, V, Ryden, LE, Cannom, DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006), e257–e354.
30. 30 Groenveld, HF, Crijns, HJ, Van den Berg, MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 58 (2011), 1795–1803.
31. 31 Smit, MD, Crijns, HJ, Tijssen, JG, et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol 58 (2011), 942–949.
32. 32 Verma, A, Cairns, JA, Mitchell, LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 30 (2014), 1114–1130.
33. 33 Ponikowski, P, Voors, AA, Anker, SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016, 10.1002/ejhf.592 published online May 20.
34. 34 Hunt, SA, Abraham, WT, Chin, MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (2009), e391–e479.
35. 35 Mareev, Y, Cleland, JG, Should beta-blockers be used in patients with heart failure and atrial fibrillation?. Clin Ther 37 (2015), 2215–2224.
36. 36 Laskey, WK, Alomari, I, Cox, M, et al. Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. J Am Heart Assoc, 4, 2015, e001626.
37. 37 Rienstra, M, Damman, K, Mulder, BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 1 (2013), 21–28.
38. 38 Kotecha, D, Holmes, J, Krum, H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384 (2014), 2235–2243.
39. 39 Ahmed, A, Rich, MW, Love, TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27 (2006), 178–186.
40. 40 Corley, SD, Epstein, AE, DiwMarco, JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004), 1509–1513.
41. 41 Whitbeck, MG, Charnigo, RJ, Khairy, P, et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 34 (2013), 1481–1488.
42. 42 Gheorghiade, M, Fonarow, GC, Van Veldhuisen, DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34 (2013), 1489–1497.
43. 43 Steinberg, BA, Holmes, DN, Ezekowitz, MD, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 165 (2013), 622–629.
44. 44 Washam, JB, Stevens, SR, Lokhnygina, Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 385 (2015), 2363–2370.
45. 45 Ziff, OJ, Lane, DA, Samra, M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, 351, 2015, h4451.
46. 46 Mulder, BA, Van Veldhuisen, DJ, Crijns, HJ, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm 11 (2014), 1543–1550.
47. 47 Allen, LA, Fonarow, GC, Simon, DN, et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol 65 (2015), 2691–2698.
48. 48 Okin, PM, Hille, DA, Wachtell, K, et al. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. J Hypertens 33 (2015), 1480–1486.
49. 49 Lee, AY, Kutyifa, V, Ruwald, MH, et al. Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. Heart Rhythm 12 (2015), 2010–2017.
50. 50 Chamaria, S, Desai, AM, Reddy, PC, et al. Digoxin use to control ventricular rate in patients with atrial fibrillation and heart failure is not associated with increased mortality. Cardiol Res Pract, 2015, 2015, 314041.
51. 51 Khand, AU, Rankin, AC, Martin, W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42 (2003), 1944–1951.
52. 52 Tse, HF, Lam, YM, Lau, CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 28 (2001), 446–450.
53. 53 Brodsky, M, Saini, R, Bellinger, R, et al. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. Am Heart J 127 (1994), 572–577.
54. 54 Kochiadakis, GE, Kanoupakis, EM, Kalebubas, MD, et al. Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. Europace 3 (2001), 73–79.
55. 55 Kuck, KH, Kunze, KP, Roewer, N, et al. Sotalol-induced torsade de pointes. Am Heart J 107 (1984), 179–180.
56. 56 McKibbin, JK, Pocock, WA, Barlow, JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 51 (1984), 157–162.
57. 57 Latini, R, Tognoni, G, Maggioni, AP, et al. Amiodarone and desethylamiodarone: plasma concentrations, therapeutic effects and side effects. J Am Coll Cardiol 11 (1988), 209–210.
58. 58 Ahmed, S, Van Gelder, IC, Wiesfeld, AC, et al. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf) 75 (2011), 388–394.
59. 59 Hou, ZY, Chang, MS, Chen, CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 16 (1995), 521–528.
60. 60 Davy, JM, Herold, M, Hoglund, C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J, 156, 2008, 527.
61. 61 Connolly, SJ, Camm, AJ, Halperin, JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365 (2011), 2268–2276.
62. 62 Farshi, R, Kistner, D, Sarma, JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 33 (1999), 304–310.
63. 63 Ulimoen, SR, Enger, S, Carlson, J, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 111 (2013), 225–230.
64. 64 Ulimoen, SR, Enger, S, Pripp, AH, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 35 (2014), 517–524.
65. 65 Ulimoen, SR, Enger, S, Norseth, J, et al. Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation. Clin Cardiol 37 (2014), 422–427.
66. 66 Nieuwlaat, R, Capucci, A, Camm, AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005), 2422–2434.
67. 67 Lip, GY, Laroche, C, Dan, GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16 (2014), 308–319.
68. 68 Ozcan, C, Jahangir, A, Friedman, PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344 (2001), 1043–1051.
69. 69 Wilkoff, BL, Cook, JR, Epstein, AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002), 3115–3123.
70. 70 Brignole, M, Auricchio, A, Baron-Esquivias, G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 34 (2013), 2281–2329.
71. 71 Brignole, M, Botto, G, Mont, L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 32 (2011), 2420–2429.
72. 72 Curtis, AB, Worley, SJ, Adamson, PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 368 (2013), 1585–1593.
73. 73 Wang, RX, Lee, HC, Hodge, DO, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 10 (2013), 696–701.
74. 74 Van Gelder, IC, Van Veldhuisen, DJ, Crijns, HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 152 (2006), 420–426.
75. 75 Van Gelder, IC, Phan, HM, Wilkoff, BL, et al. Prognostic significance of atrial arrhythmias in a primary prevention ICD population. Pacing Clin Electrophysiol 34 (2011), 1070–1079.
76. 76 Fischer, A, Ousdigian, KT, Johnson, JW, et al. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm 9 (2012), 24–31.
77. 77 Wilkoff, BL, Williamson, BD, Stern, RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 52 (2008), 541–550.
78. 78 Gasparini, M, Auricchio, A, Metra, M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29 (2008), 1644–1652.
79. 79 Gasparini, M, Leclercq, C, Lunati, M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 1 (2013), 500–507.
80. 80 Upadhyay, GA, Steinberg, JS, Managing atrial fibrillation in the CRT patient: controversy or consensus?. Heart Rhythm 9 (2012), S51–S59.
81. 81 Khan, MN, Jais, P, Cummings, J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359 (2008), 1778–1785.
82. 82 Ganesan, AN, Brooks, AG, Roberts-Thomson, KC, et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 59 (2012), 719–726.
83. 83 Poole, JE, Gleva, MJ, Mela, T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 122 (2010), 1553–1561.
84. 84 Bun, SS, Latcu, DG, Marchlinski, F, et al. Atrial flutter: more than just one of a kind. Eur Heart J 36 (2015), 2356–2363.
85. 85 Crijns, HJ, Van Gelder, IC, Lie, KI, Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 62 (1988), 1303–1306.
86. 86 Page, RL, Joglar, JA, Caldwell, MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 67 (2016), e27–115.
87. 87 Boriani, G, Padeletti, L, Santini, M, et al. Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. Am Heart J 154 (2007), 193–200.
88. 88 Parvez, B, Chopra, N, Rowan, S, et al. A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 59 (2012), 49–56.
89. 89 Rau, T, Dungen, HD, Edelmann, F, et al. Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 92 (2012), 21–28.
90. 90 Kao, DP, Davis, G, Aleong, R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail 15 (2013), 324–333.
91. 91 Bianchi, S, Rossi, P, Schauerte, P, et al. Increase of ventricular interval during atrial fibrillation by atrioventricular node vagal stimulation: chronic clinical atrioventricular-nodal stimulation download study. Circ Arrhythm Electrophysiol 8 (2015), 562–568.